ANI Pharmaceuticals, Inc. (ANIP)

In the past six months, ANI Pharmaceuticals' stock has been impacted by several key events. The company reported Q3 2025 earnings per share (EPS) of $2.04, surpassing estimates, with quarterly revenue also exceeding expectations. In Q1 2026, ANI Pharmaceuticals delivered a robust financial performance, significantly exceeding market expectations, with the stock rising by 4.81% in premarket trading. Concurrent with its Q1 2026 earnings, ANI Pharmaceuticals raised its full-year 2026 financial guidance. Effective May 8, 2026, ANI's board of directors authorized a new 3-year share repurchase program to buy back up to $100 million in common stock. In May 2026, Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" to a "strong-buy" rating. Over the past 52 weeks, ANIP's stock has traded between a low of $56.71 and a high of $99.50.

ANI Pharmaceuticals experiences demand seasonality for its products, particularly impacting Cortrophin Gel. The first quarter of the year is affected by seasonality related to insurance reverifications, which can take longer to clear in January and February. Despite this, the company has reported strong demand and growth for Cortrophin Gel.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on providing high-quality branded and generic prescription pharmaceuticals. The company operates through two segments: Rare Disease and Brands, and Generics and Other. The Rare Disease and Brands segment includes proprietary branded medicines and acquired branded products. The Generics and Other segment focuses on developing, manufacturing, and marketing a broad portfolio of generic products, along with related royalties and services. ANI's product offerings encompass various forms, including injectables, capsules, and oral solid dose products.

ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota, with a commercial headquarters in Princeton, New Jersey. The company operates three U.S. manufacturing facilities: two in Baudette, Minnesota, and one in East Windsor, New Jersey. While the company develops, manufactures, and markets products internationally, its revenue is primarily U.S.-derived.

In the past year, ANI Pharmaceuticals has demonstrated strong financial performance and received positive analyst sentiment, contributing to a favorable brand perception. The company's successful execution in its Rare Disease and Generics segments, including significant revenue growth and consistent new product launches, reflects positively on its operational capabilities and market standing. Analyst upgrades to "strong-buy" ratings further indicate a positive view of the company's prospects and management.

Institutional investors hold a significant portion of ANI Pharmaceuticals' stock. Major institutional holders include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Approximately 84.8% of the company's shares are held by institutions, 7.0% by individuals, and 4.6% by other entities.